- $98.13m
- $152.41m
- $78.23m
OptiNose Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: OptiNose Board Increases Size Of Board From Eight To Nine Members
OptiNose Inc reports results for the quarter ended in December - Earnings Summary
U.S. STOCKS ON THE MOVE-Gilead, Upwork, Peabody Energy
U.S. STOCKS ON THE MOVE-Mosaic, Raytheon, Capri
OptiNose jumps 60% as chronic sinus treatment meets main goals in study
Brief: OptiNose Inc - Reports Positive Top-Line Results In Reopen1, A Landmark Phase 3 Trial For Xhance In Chronic Sinusitis
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
OptiNose Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: OptiNose Announces Appointment Of Two New Members To Board
OptiNose hits record low on dismal revenue outlook, discounted stock offer
Brief: Optinose Announces Pricing Of Public Offering Of Common Stock
OptiNose eyes record low open on dismal revenue outlook, stock sale plan
OptiNose Inc reports results for the quarter ended in September - Earnings Summary
Brief: Optinose Announces Proposed Public Offering Of Common Stock
Brief: OptiNose Reports Q3 Loss Per Share Of $0.32
OptiNose Inc expected to post a loss of 36 cents a share - Earnings Preview
OptiNose Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Optinose Inc Completes Patient Recruitment In Second Pivotal Trial